fluorodeoxyuridine + fluorouracil + oxaliplatin

This is a combination chemotherapy regimen consisting of three antineoplastic agents: - **Fluorodeoxyuridine (FUDR):** A pyrimidine analog and antimetabolite that inhibits thymidylate synthase, leading to disruption of DNA synthesis and repair. - **Fluorouracil (5-FU):** Another pyrimidine analog that acts as an antimetabolite, inhibiting thymidylate synthase and incorporating into RNA and DNA, thereby interfering with nucleic acid function and protein synthesis[2][6][8]. - **Oxaliplatin:** A platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription. The combination targets rapidly dividing cancer cells through multiple mechanisms affecting both DNA synthesis/repair (via FUDR/5-FU) and direct DNA damage/crosslinking (via oxaliplatin). Such combinations are primarily used in the treatment of colorectal cancer, especially metastatic or advanced cases. While regimens like FOLFOX commonly combine 5-fluorouracil with oxaliplatin (and leucovorin), the specific triple combination with fluorodeoxyuridine is less common but mechanistically similar[1][3][4].